Artificial intelligence is becoming core infrastructure in biopharmaceutical development, rapidly changing how drug candidates are found and validated. AstraZeneca says computing now reinforces the entire process from design and production to verification and analysis, shortening development cycles and boosting productivity. The company uses a build-measure-learn loop, multimodal datasets and precision screening, and is building an AI- and robot-enabled lab in Cambridge, Massachusetts. Executives say de novo, fully AI-generated biologics are an industry goal but require richer data, benchmarks and talent, with human oversight remaining central.

MegazoneCloud said it shared strategies for industrial use of quantum technology with about 30 University of Texas at Austin McCombs School of Business MBA students. The company hosted 37 visitors on March 10 at its industry-academia-research center in Gwacheon for a Quantum & Cloud Strategy Day event as part of the MBA program’s Global Connections field study. It introduced quantum technology applications across sectors and discussed corporate strategic responses.